The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection
People with type 2 diabetes mellitus (T2DM) are at high risk of developing cardiovascular disease (CVD) and kidney disease. This enhanced cardio-renal risk persists despite improvements in care and treatments over the last 20 years. Intensive glucose control alone does not substantially reduce the r...
| מחבר ראשי: | |
|---|---|
| פורמט: | Article |
| שפה: | Russian |
| יצא לאור: |
«FIRMA «SILICEA» LLC
2021-04-01
|
| סדרה: | Российский кардиологический журнал |
| נושאים: | |
| גישה מקוונת: | https://russjcardiol.elpub.ru/jour/article/view/4323 |